ABBV vs. VTRS: A Head-to-Head Stock Comparison

Updated on November 21, 2025

Here’s a clear look at ABBV and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ABBV	VTRS
Company Name	AbbVie Inc.	Viatris Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Pharmaceuticals
Market Capitalization	413.71 billion USD	12.54 billion USD
Exchange	NYSE	NasdaqGS
Listing Date	January 2, 2013	March 17, 1980
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ABBV and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. VTRS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ABBV	VTRS
5-Day Price Return	6.24%	5.41%
13-Week Price Return	12.42%	1.04%
26-Week Price Return	23.60%	21.96%
52-Week Price Return	36.40%	-17.54%
Month-to-Date Return	6.57%	3.47%
Year-to-Date Return	30.76%	-13.90%
10-Day Avg. Volume	6.26M	11.32M
3-Month Avg. Volume	5.46M	9.24M
3-Month Volatility	24.91%	30.81%
Beta	0.33	0.81

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max: 96.19%
Q3: 12.45%
Median: -16.39%
Q1: -47.43%
Min: -131.19%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

VTRS

-22.69%

Pharmaceuticals Industry

Max: 38.95%
Q3: 20.34%
Median: 11.59%
Q1: 3.32%
Min: -10.91%

VTRS has a negative Return on Equity of -22.69%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ABBV vs. VTRS: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

ABBV

4.00%

Biotechnology Industry

Max: 84.13%
Q3: 19.34%
Median: -1.39%
Q1: -117.64%
Min: -296.77%

ABBV’s Net Profit Margin of 4.00% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

VTRS

-26.13%

Pharmaceuticals Industry

Max: 39.07%
Q3: 19.28%
Median: 13.48%
Q1: 5.73%
Min: -8.86%

VTRS has a negative Net Profit Margin of -26.13%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ABBV vs. VTRS: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

ABBV

15.16%

Biotechnology Industry

Max: 78.85%
Q3: 20.86%
Median: 0.51%
Q1: -128.29%
Min: -315.84%

ABBV’s Operating Profit Margin of 15.16% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

VTRS

-21.26%

Pharmaceuticals Industry

Max: 45.58%
Q3: 24.35%
Median: 18.05%
Q1: 7.58%
Min: -11.88%

VTRS has a negative Operating Profit Margin of -21.26%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ABBV vs. VTRS: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	ABBV	VTRS
Return on Equity (TTM)	95.59%	-22.69%
Return on Assets (TTM)	1.76%	-9.45%
Net Profit Margin (TTM)	4.00%	-26.13%
Operating Profit Margin (TTM)	15.16%	-21.26%
Gross Profit Margin (TTM)	71.16%	39.36%

Financial Strength

Current Ratio (MRQ)

ABBV

0.72

Biotechnology Industry

Max: 15.83
Q3: 7.97
Median: 4.06
Q1: 2.64
Min: 0.72

ABBV’s Current Ratio of 0.72 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

VTRS

1.35

Pharmaceuticals Industry

Max: 5.45
Q3: 2.99
Median: 1.98
Q1: 1.29
Min: 0.78

VTRS’s Current Ratio of 1.35 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

ABBV vs. VTRS: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max: 1.27
Q3: 0.62
Median: 0.13
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

VTRS

0.95

Pharmaceuticals Industry

Max: 1.79
Q3: 0.78
Median: 0.31
Q1: 0.08
Min: 0.00

VTRS’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

ABBV vs. VTRS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max: 72.37
Q3: 1.71
Median: -15.18
Q1: -65.75
Min: -166.46

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

VTRS

-0.13

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 10.15
Q1: 2.37
Min: -42.71

VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ABBV vs. VTRS: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	ABBV	VTRS
Current Ratio (MRQ)	0.72	1.35
Quick Ratio (MRQ)	0.47	0.68
Debt-to-Equity Ratio (MRQ)	49.22	0.95
Interest Coverage Ratio (TTM)	2.70	-0.13

Growth

Revenue Growth

ABBV vs. VTRS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. VTRS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.80%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV’s Dividend Yield of 2.80% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

VTRS

4.84%

Pharmaceuticals Industry

Max: 6.72%
Q3: 3.48%
Median: 1.90%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 4.84%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

ABBV vs. VTRS: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

362.90%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 362.90%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

VTRS

137.04%

Pharmaceuticals Industry

Max: 199.58%
Q3: 85.87%
Median: 49.36%
Q1: 1.12%
Min: 0.00%

VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

ABBV vs. VTRS: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	ABBV	VTRS
Dividend Yield (TTM)	2.80%	4.84%
Dividend Payout Ratio (TTM)	362.90%	137.04%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

171.97

Biotechnology Industry

Max: 115.91
Q3: 56.76
Median: 21.80
Q1: 15.79
Min: 4.51

At 171.97, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

VTRS

Pharmaceuticals Industry

Max: 52.64
Q3: 29.89
Median: 20.77
Q1: 13.37
Min: 5.71

P/E Ratio data for VTRS is currently unavailable.

ABBV vs. VTRS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

6.89

Biotechnology Industry

Max: 58.56
Q3: 29.31
Median: 8.30
Q1: 4.89
Min: 0.86

ABBV’s P/S Ratio of 6.89 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

VTRS

0.83

Pharmaceuticals Industry

Max: 8.74
Q3: 4.66
Median: 2.37
Q1: 1.67
Min: 0.11

In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.83 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

ABBV vs. VTRS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max: 17.92
Q3: 10.38
Median: 4.78
Q1: 2.85
Min: 0.78

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

VTRS

0.76

Pharmaceuticals Industry

Max: 9.86
Q3: 5.28
Median: 2.48
Q1: 1.57
Min: 0.59

VTRS’s P/B Ratio of 0.76 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

ABBV vs. VTRS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	ABBV	VTRS
Price-to-Earnings Ratio (TTM)	171.97	--
Price-to-Sales Ratio (TTM)	6.89	0.83
Price-to-Book Ratio (MRQ)	261.01	0.76
Price-to-Free Cash Flow Ratio (TTM)	20.86	7.26